FDA Access to Patient Drug Utilization Data

The Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) focuses on providing comprehensive outpatient prescription and patient-level drug utilization data subscription services. The contract enables FDA personnel to access sophisticated, real-time, multi-user data platforms that offer nationwide prescription tracking and patient medication usage insights. The primary objective of this contract vehicle is to support epidemiological drug safety studies by delivering HIPAA-compliant, longitudinal datasets that can be analyzed for national drug utilization patterns and patient exposure trends.

Task orders under this IDIQ are likely to involve data subscription services from commercial healthcare analytics providers, with potential values ranging from $100,000 to $5 million annually. The contract supports direct, unlimited Internet-based access to prescription claims data, enabling researchers to examine patient-level medication use, concomitant drug interactions, and national prescription trends. While specific task order details are not provided, typical awardees might include healthcare data analytics firms such as IQVIA, Optum, or similar organizations specializing in comprehensive prescription data aggregation and analysis. The contract's multi-user environment and robust data download capabilities suggest a focus on supporting comprehensive epidemiological research within the FDA's drug safety evaluation processes.